Mechanism of action
Pseudoephedrine is a stereoisomer of ephedrine and functions as an indirect sympathomimetic agent. Its primary mechanism involves displacing norepinephrine from presynaptic storage vesicles in sympathetic nerve terminals, leading to increased synaptic norepinephrine concentrations. This released norepinephrine then activates alpha-1 adrenergic receptors on vascular smooth muscle in the nasal mucosa.
The alpha-1 receptor stimulation causes vasoconstriction of dilated arterioles and venous sinusoids within the nasal passages, reducing blood flow to the swollen tissues. This vasoconstriction decreases mucosal edema and hyperemia, resulting in reduced nasal airway resistance and improved nasal patency. Pseudoephedrine also has mild direct alpha- and beta-adrenergic agonist activity, though this is much weaker than its indirect effects.
Unlike topical decongestants such as oxymetazoline, pseudoephedrine does not cause significant rebound congestion (rhinitis medicamentosa) because it acts systemically rather than through direct local receptor activation. The drug has minimal effects on beta-2 receptors, distinguishing it from bronchodilators, though some beta-1 cardiac stimulation can occur at therapeutic doses.
- Pseudoephedrine causes vasoconstriction via indirect alpha-adrenergic stimulation by displacing norepinephrine from presynaptic vesicles
- Contraindicated with MAOIs due to risk of hypertensive crisis; must wait 14 days after MAOI discontinuation
- Does NOT cause rebound congestion (rhinitis medicamentosa) unlike topical decongestants because it acts systemically
- Can elevate blood pressure and cause tachycardia; use with caution in hypertension and cardiovascular disease
- Urinary retention risk in men with benign prostatic hyperplasia due to alpha-adrenergic effects on bladder neck
- 55-75% excreted unchanged in urine; elimination is pH-dependent (alkaline urine decreases clearance)
- Behind-the-counter in US due to use as methamphetamine precursor; purchase limits enforced
- More effective than oral phenylephrine due to higher bioavailability (90% vs 10-38%)
Indications
Pseudoephedrine is indicated for temporary relief of nasal congestion associated with:
- Upper respiratory tract infections – Common cold, acute viral rhinitis
- Allergic rhinitis – Seasonal and perennial allergic rhinitis (often combined with antihistamines)
- Sinusitis – Acute and chronic rhinosinusitis to improve sinus drainage
- Eustachian tube congestion – Associated with otitis media or barotrauma
Pseudoephedrine is frequently formulated in combination products with antihistamines, analgesics, or cough suppressants for multi-symptom cold and allergy relief. It provides symptomatic relief only and does not treat the underlying cause of congestion. The drug is available over-the-counter in many countries but is subject to purchase restrictions due to its potential use in illegal methamphetamine synthesis.
Pharmacokinetics
Absorption and distribution: Pseudoephedrine is rapidly and nearly completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations occur within one to three hours. The drug is widely distributed throughout body tissues and crosses the blood-brain barrier to a limited extent, which accounts for its CNS stimulant effects.
Metabolism: Pseudoephedrine undergoes incomplete hepatic metabolism. A significant portion is metabolized by N-demethylation and oxidative deamination, but the extent varies among individuals. Although monoamine oxidase can metabolize pseudoephedrine, this is a minor pathway.
Elimination: The primary route of elimination is renal excretion. Between 55-75% of a dose is excreted unchanged in urine. The elimination half-life ranges from 5-8 hours in adults but is highly pH-dependent. Urinary acidification increases renal clearance and shortens the half-life, while alkalinization prolongs it. This pH dependence has clinical relevance in overdose management and drug interaction considerations.
Special populations: In patients with renal impairment, clearance is reduced and dosing adjustments may be necessary. Extended-release formulations provide 12-24 hour duration of action.
Adverse effects
Pseudoephedrine's adverse effects result primarily from systemic sympathomimetic activity:
Cardiovascular
- Hypertension – Elevation of blood pressure through peripheral vasoconstriction
- Tachycardia and palpitations – Beta-1 adrenergic stimulation
- Arrhythmias – Rare but reported, particularly in susceptible individuals
Central nervous system
- Nervousness and restlessness
- Insomnia – Especially with evening doses
- Dizziness and headache
- Tremor
- Seizures – Rare, usually with overdose
Genitourinary
- Urinary retention – Particularly in men with prostatic hypertrophy due to alpha-adrenergic effects on bladder neck
- Dysuria
Other effects
- Dry mouth
- Nausea
- Anorexia
Adverse effects are generally dose-dependent and more common in sensitive individuals, the elderly, and those with pre-existing cardiovascular conditions. Extended-release formulations may reduce the incidence of CNS side effects compared to immediate-release preparations.
Contraindications and warnings
Absolute contraindications
- Severe hypertension or severe coronary artery disease – Risk of cardiovascular complications
- Concurrent or recent MAOI use (within 14 days) – Risk of hypertensive crisis due to potentiation of sympathomimetic effects
- Hypersensitivity to pseudoephedrine or other sympathomimetics
Relative contraindications and warnings
- Hypertension – Even mild to moderate hypertension warrants caution; blood pressure should be monitored
- Cardiovascular disease – Ischemic heart disease, arrhythmias, or history of stroke
- Hyperthyroidism – Enhanced sensitivity to sympathomimetic amines
- Diabetes mellitus – May affect glucose control
- Prostatic hypertrophy – Increased risk of urinary retention
- Narrow-angle glaucoma – Mydriatic effects may precipitate acute angle closure
- Pregnancy – Category C; use only if benefit outweighs risk. First-trimester use has been associated with gastroschisis in some studies, though causality is debated
- Elderly patients – Increased sensitivity to sympathomimetic effects
Precautions
Pseudoephedrine is a CNS stimulant and may impair judgment or coordination. Patients should be cautioned about operating machinery until individual response is known. The drug has potential for misuse in methamphetamine production, leading to regulatory restrictions on purchase quantities in many jurisdictions.
Drug interactions
Major interactions
- Monoamine oxidase inhibitors (MAOIs) – Concurrent use with nonselective MAOIs (phenelzine, tranylcypromine) or within 14 days of discontinuation is contraindicated. MAOIs prevent breakdown of norepinephrine, and the combination can cause severe hypertensive crisis with potential for stroke or myocardial infarction.
- Antihypertensive medications – Pseudoephedrine antagonizes the effects of antihypertensives including beta-blockers, methyldopa, reserpine, and guanethidine through opposing sympathetic effects. Blood pressure elevation may reduce therapeutic efficacy.
Moderate interactions
- Urinary alkalinizers – Sodium bicarbonate, acetazolamide, and other alkalinizing agents decrease renal clearance of pseudoephedrine by promoting tubular reabsorption, potentially increasing plasma levels and adverse effects.
- Urinary acidifiers – Ammonium chloride and acidifying agents increase renal clearance, potentially reducing efficacy.
- Other sympathomimetics – Additive effects with other decongestants, caffeine, or stimulants may increase adverse effects such as tachycardia, hypertension, and CNS stimulation.
- Digoxin – Increased risk of arrhythmias when used concurrently.
- Tricyclic antidepressants – May enhance the cardiovascular effects of pseudoephedrine.
Clinical considerations
Patients should be advised to read labels of over-the-counter medications to avoid inadvertent duplication of sympathomimetic agents. Healthcare providers should obtain a complete medication history including supplements and OTC products before recommending pseudoephedrine.
Clinical pearls
- Phenylephrine vs pseudoephedrine: Oral phenylephrine has very low bioavailability of approximately 10-38% due to extensive first-pass metabolism and questionable efficacy, whereas pseudoephedrine has approximately 90% bioavailability and is more effective as an oral decongestant. This is why pseudoephedrine remains behind-the-counter despite purchase restrictions.
- Rebound congestion: Unlike topical decongestants (oxymetazoline, phenylephrine nasal spray), pseudoephedrine does not cause rhinitis medicamentosa because it acts systemically rather than through direct prolonged activation of nasal alpha receptors. This makes it safer for extended use when needed.
- Athletic drug testing: Pseudoephedrine was previously banned by the World Anti-Doping Agency due to potential performance enhancement but was removed from the prohibited list in 2004. However, it is still monitored and athletes should check current regulations.
- Methamphetamine synthesis: Pseudoephedrine is a precursor in illegal methamphetamine production via reduction reactions. This has led to the Combat Methamphetamine Epidemic Act in the United States, requiring behind-the-counter sales, purchase limits, and buyer identification.
- Pregnancy considerations: While classified as Category C, first-trimester exposure has shown possible association with gastroschisis in epidemiologic studies. Topical nasal saline or corticosteroids are generally preferred during pregnancy when possible.
- Timing of doses: To minimize insomnia, the last daily dose should be taken several hours before bedtime, typically no later than early afternoon for immediate-release formulations.
- Alternative for hypertensive patients: Intranasal corticosteroids or antihistamines with antihistaminic properties may be safer alternatives for chronic nasal congestion in patients with cardiovascular disease or hypertension who cannot use sympathomimetics.
Practice questions
1. A 45-year-old man with well-controlled hypertension on lisinopril presents to the pharmacy requesting an over-the-counter medication for nasal congestion from a cold. He also takes tranylcypromine for depression. Which of the following is the most appropriate recommendation?
2. A 68-year-old man with benign prostatic hyperplasia complains of difficulty urinating after starting pseudoephedrine for sinus congestion 3 days ago. Which pharmacologic mechanism best explains this adverse effect?
3. A medical student reads that pseudoephedrine does not cause rhinitis medicamentosa, unlike oxymetazoline nasal spray. Which of the following best explains this difference?
Frequently asked questions
How does pseudoephedrine work?
Pseudoephedrine works by displacing norepinephrine from nerve terminals, which then activates alpha-1 adrenergic receptors on blood vessels in the nasal passages. This causes vasoconstriction of swollen nasal mucosa, reducing blood flow and edema, which relieves nasal congestion. Unlike topical decongestants, it works systemically after oral absorption and does not cause rebound congestion.
What are the side effects of pseudoephedrine?
Common side effects include nervousness, restlessness, insomnia, increased heart rate, elevated blood pressure, and headache. Less common effects include urinary retention (especially in men with enlarged prostate), tremor, dizziness, dry mouth, and palpitations. These adverse effects result from systemic sympathomimetic activity affecting the cardiovascular and central nervous systems. Patients with hypertension or heart disease are at higher risk for cardiovascular complications.
Is pseudoephedrine a controlled substance?
Pseudoephedrine is not a federally controlled substance under the DEA scheduling system, but it is regulated under the Combat Methamphetamine Epidemic Act because it can be used to synthesize methamphetamine. In the United States, it must be sold behind the pharmacy counter, purchase quantities are limited, buyers must show identification, and sales are logged. Individual states may have additional restrictions on purchase amounts and frequency.
Pseudoephedrine vs phenylephrine — what is the difference?
Pseudoephedrine and phenylephrine are both sympathomimetic decongestants, but pseudoephedrine is significantly more effective when taken orally. Pseudoephedrine has approximately 90% oral bioavailability and works indirectly by releasing norepinephrine, while oral phenylephrine has only about 10-38% bioavailability due to extensive first-pass metabolism. Phenylephrine is available without restrictions on pharmacy shelves, whereas pseudoephedrine requires identification and is kept behind the counter due to methamphetamine synthesis concerns.
Can you take pseudoephedrine with high blood pressure?
Pseudoephedrine should be used with caution in patients with high blood pressure and may be contraindicated in those with severe hypertension. It can elevate blood pressure through systemic vasoconstriction and may reduce the effectiveness of antihypertensive medications. Patients with controlled hypertension should consult their physician before use and monitor their blood pressure. Alternative treatments such as intranasal corticosteroids or saline irrigation are generally safer options for nasal congestion in hypertensive patients.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R01BA02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.